You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Keynote A10

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial (Pembrolizumab)

Active, not recruiting
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • (no location specified)
Dec 15, 2022

Emulation of KEYNOTE-189 Trial Using Electronic Health Records

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Metastatic Lung Cancer
  • Boston, Massachusetts
    Aetion
Jun 14, 2023

Hepatocellular Carcinoma Trial (biological, drug, other)

Completed
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 30, 2022

Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab)

Completed
Has Results
  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma
  • pembrolizumab
  • (no location specified)
Aug 18, 2022

Renal Cell Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • (no location specified)
Aug 17, 2022

Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma Trial (XNW5004, Pembrolizumab 25 mg/mL Solution for

Not yet recruiting
  • Carcinoma
  • +7 more
  • XNW5004
  • Pembrolizumab 25 mg/mL Solution for Injection
  • (no location specified)
Aug 31, 2023

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial (pembrolizumab, cisplatin, 5-FU)

Completed
Has Results
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • pembrolizumab
  • +3 more
  • (no location specified)
Jul 13, 2022

NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
Aug 18, 2022

Renal Cell Carcinoma Trial (Pembrolizumab, Axitinib, Sunitinib)

Active, not recruiting
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 17, 2022

Urothelial Cancer Trial (pembrolizumab)

Completed
Has Results
  • Urothelial Cancer
  • pembrolizumab
  • (no location specified)
Aug 18, 2022

Colorectal Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Colorectal Carcinoma
  • Pembrolizumab
  • (no location specified)
Mar 29, 2022

Non-Small-Cell Lung Carcinoma Trial (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • (no location specified)
Aug 16, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022

Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab, paclitaxel, docetaxel)

Completed
Has Results
  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma
  • pembrolizumab
  • +3 more
  • (no location specified)
May 5, 2022

Ovarian Tumors Trial (Pembrolizumab)

Completed
Has Results
  • Ovarian Neoplasms
  • Pembrolizumab
  • (no location specified)
Feb 23, 2022

Triple Negative Breast Cancer (TNBC) Trial (Pembrolizumab, Nab-paclitaxel, Paclitaxel)

Active, not recruiting
Has Results
  • Triple Negative Breast Cancer (TNBC)
  • Pembrolizumab
  • +5 more
  • (no location specified)
Jul 15, 2022

Advanced Malignancies Trial in Denmark, Hungary, Russian Federation (BI-1808, Pembrolizumab 25 Mg/mL Solution for Injection)

Recruiting
  • Advanced Malignancies
  • BI-1808
  • Pembrolizumab 25 Mg/mL Solution for Injection
  • Copenhagen, Denmark
  • +11 more
Sep 9, 2022

Advanced Cancer, Anal Carcinoma, Anal Cancer Trial in Worldwide (pembrolizumab)

Recruiting
  • Advanced Cancer
  • +24 more
  • pembrolizumab
  • Los Angeles, California
  • +21 more
Jan 18, 2023

Cancer Trial in Houston (LVGN6051)

Recruiting
  • Cancer
  • LVGN6051
  • Houston, Texas
    MD Anderson Cancer Center
Nov 18, 2021

NSCLC Trial (Pembrolizumab, Docetaxel)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 18, 2022

Melanoma Trial in Worldwide (Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B)

Active, not recruiting
  • Melanoma
  • Pembrolizumab Dose C
  • +3 more
  • Orange, New South Wales, Australia
  • +14 more
Jan 19, 2023

Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • Nagoya, Aichi, Japan
  • +9 more
Jan 23, 2023